H35 H35.3
Conditions
Interventions
Group 1: Patients with retinal diseases who are being treated with intravitreal injection of anti-VEGf agents or steroid implants.
Group 2: patients with moderate or mild retinal disease (i.e. diabeti
Sponsors
Augenklinik des Universitätsklinikums Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: for Treatment Group: retinal disease that requires intravitreal anti-VEGF or steroid therapy for Control Group: no specific inclusion criteria expect a healthy retina
Exclusion criteria
Exclusion criteria: inability to consent, history of retinal surgery, macular holes, amblyopia, media opacities that compromises the Image Quality (i.e. scarring in the central part of the Cornea), uncontrolled glaucoma, refraction error > 6diotre (spherical equivalent), best corrected visual acuity below 0,05
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the yearly change of morphological Parameter (i.e. vessel Density or retina thickness) in arm 1 and 2 (up to fifth year after start of treatment). OCT(A) from the first visit will be compared to OCT(A) from every following yearly visits. | — |
Secondary
| Measure | Time frame |
|---|---|
| secondary endpoint is of functional nature, i.e. the best corrected visual acuity after 1 year in arm 1 and 2. Visual acuity from first visit will be compared to visual acuity from 1-year visit. | — |
Countries
Germany
Contacts
Public ContactLucy Kessler
Augenklinik des Universitätsklinikums Heidelberg
Outcome results
None listed